Celmatix
Celmatix is a preclinical-stage women's health biotech developing first-in-class therapeutics for infertility, endometriosis, PCOS, and ovarian aging using the DEC-Tec discovery platform, monetizing its pipeline through licensing, asset sales, and grants.
- Company typePrivate
- Founded2009
- HeadquartersNew York, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Celmatix does
Celmatix is a US-based, preclinical-stage women's health biotechnology company founded in 2009 and headquartered in New York City. It develops novel therapeutics targeting ovarian biology and female reproductive health across four primary indications: infertility, endometriosis, polycystic ovary syndrome (PCOS), and ovarian aging. Its pipeline centers on first-in-class candidates including an oral follicle-stimulating hormone (FSH) receptor agonist for fertility, a Jun N-terminal kinase (JNK) inhibitor for endometriosis pain and inflammation, anti-Müllerian hormone (AMH)-targeting antibodies for ovarian function, and peripherally restricted melatonin receptor agonists for PCOS and related conditions. Discovery leverages the DNA-Encoded Chemistry Technology (DEC-Tec) platform housed at Baylor College of Medicine's Center for Drug Discovery and is informed by the largest published genetic dataset on endometriosis, assembled with the University of Oxford and 24 collaborating institutions.
Celmatix operates as a B2B asset-development biotech rather than a commercial product company. Its revenue model is built on licensing deals, asset sales, and milestone payments from pharmaceutical partners, supplemented by non-dilutive research grants. In March 2026, Gedeon Richter acquired Celmatix's discovery portfolio — encompassing the oral FSH receptor agonist, JNK inhibitor, and AMH antibody programs — in exchange for upfront and milestone payments; Celmatix retained certain residual programs and continues to operate. The company also has a free consumer-facing digital tool, MyFertivity Compass, that provides fertility-related analytics without disclosed monetization. Headcount sits in the 101–250 range, consistent with a preclinical biotech sustaining multiple discovery programs alongside an academic and pharma partnership network that includes Aché Laboratórios, Evotec, and Baylor College of Medicine.
Celmatix firmographics
Firmographics- Name
- Celmatix
- Legal name
- Celmatix Inc.
- Website
- https://celmatix.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Celmatix is a preclinical-stage women's health biotech developing first-in-class therapeutics for infertility, endometriosis, PCOS, and ovarian aging using the DEC-Tec discovery platform, monetizing its pipeline through licensing, asset sales, and grants.
- Ownership category
- akta.pro rank
Celmatix industry classification
Industry- Product category
- Women's Health Therapeutics / Reproductive Health Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Celmatix is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Celmatix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Licensing and asset sales: Celmatix generates revenue through licensing agreements and asset sales to pharmaceutical companies. In March 2026, Gedeon Richter acquired Celmatix's women's health discovery portfolio including upfront and milestone payments as development progresses.
- Research funding and grants: Non-dilutive funding from government agencies such as ARPA-H to support early-stage research efforts in women's health therapeutics.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Celmatix product offering
Product offeringCore offering
Celmatix is a preclinical-stage women's health biotech that discovers and develops novel therapeutics targeting ovarian biology and reproductive conditions including infertility, endometriosis, PCOS, and ovarian aging. Its core assets are drug programs — an oral FSH receptor agonist, a JNK inhibitor, AMH-targeting antibodies, and peripherally preferred melatonin receptor agonists — that are advanced through internal R&D and academic collaborations and ultimately licensed or sold to pharmaceutical partners. The company also offers a free consumer-facing fertility insights tool, MyFertility Compass.
Product overview
Celmatix is a women's health biotech company dedicated to translating advances in female biology into novel therapeutics. The company operates multiple drug development programs including: an oral FSH receptor agonist for fertility treatment; a JNK inhibitor for endometriosis; AMH-targeting antibodies for ovarian aging and lifespan extension; and a melatonin receptor agonist program for PCOS and related conditions. The company also offers MyFertility Compass, a free online data analytics tool. Following the March 2026 acquisition by Gedeon Richter, the women's health discovery portfolio including the FSH receptor agonist, JNK inhibitor, and AMH programs is now part of Gedeon Richter's pipeline.
Differentiator
Problem solved
Functional benefit
Products and services
- Oral FSH Receptor Agonist Program First-in-class oral Follicle-Stimulating Hormone (FSH) receptor agonist drug program intended to enable more patient-friendly ovarian stimulation for fertility treatment. Lead compound was nominated in October 2024, and the program was part of the portfolio acquired by Gedeon Richter in March 2026.
- JNK Inhibitor Program (Endometriosis) Novel Jun N-terminal kinase (JNK) inhibitor drug program representing a potential non-hormonal immunotherapy approach for endometriosis targeting both pain and inflammation, with potential expansion to PCOS and ovarian aging. Developed using the DEC-Tec platform at Baylor College of Medicine. Launched January 2025 and part of the portfolio acquired by Gedeon Richter in March 2026.
- AMH-Targeting Antibodies Program Early-stage therapeutic antibody program targeting Anti-Müllerian Hormone (AMH), including both agonists and antagonists, designed to provide control over ovarian folliculogenesis and potentially extend ovarian function throughout a woman's lifespan. Developed with support from a $3.5M ARPA-H award and part of the portfolio acquired by Gedeon Richter in March 2026.
- Melatonin Receptor Agonist Program Drug program targeting peripherally preferred melatonin receptors outside the central nervous system (CNS), initially for PCOS, with potential expansion to endometriosis and menopausal symptoms. Subject of a collaboration and license option agreement with Aché Laboratórios announced in August 2023.
- MyFertility Compass Free online data analytics tool providing fertility-related insights and guidance to individual users, hosted at myfertilitycompass.io as part of Celmatix's consumer-facing digital presence.
Quantifiable outcome
- First-in-class oral FSH receptor agonist drug candidate nominated
- +2 more outcomes
Companies that use Celmatix
Customer profileSegments2 records
Ideal customer profiles2 records
Celmatix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Celmatix partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Gedeon RichtercoreHungarian pharmaceutical company Gedeon Richter acquired Celmatix's women's health discovery portfolio including programs spanning infertility, endometriosis, and ovarian aging. Assets include first-in-class oral FSH receptor agonist, novel JNK inhibitor for endometriosis, and early-stage AMH-targeting antibodies. Celmatix will receive upfront and milestone payments as development progresses.
- Aché LaboratórioscoreCollaboration and license option agreement with leading Brazilian pharmaceutical company to jointly investigate a novel peripherally preferred melatonin receptor agonist for Women's Health indications, starting with PCOS.
- University of OxfordcoreLong-term collaboration with researchers from University of Oxford and 24 other institutions on the largest genetic study on endometriosis to date, including DNA from 60,600 women with endometriosis and 701,900 controls. Study published in Nature Genetics.
- EvoteccoreFive-year multi-target alliance with Evotec for drug discovery. Milestone achieved when Evotec and Bayer AG advanced a second drug program centered around a novel Celmatix-identified drug target into hit-identification.
- Baylor College of MedicinecoreDrug discovery partnership utilizing the DNA-Encoded Chemistry Technology (DEC-Tec) platform at the Center for Drug Discovery for developing JNK inhibitor therapeutic candidates for endometriosis and other women's health indications.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Celmatix competitors and assessment
Company assessmentDirect peers
- ObsEva: Clinical-stage women's health biotech focused on reproductive health conditions including endometriosis and preterm labor; directly comparable in therapeutic area, modality class, and B2B pharma-partnering model.
- Myovant Sciences: Women's health biotech developing therapies for uterine fibroids, endometriosis, and prostate cancer; directly comparable specialty pharma/Biotech model targeting the same reproductive indications.
- Dare Bioscience: Women's health-focused biotech with a portfolio model spanning contraception, fertility, and menopause; directly comparable clinical-stage pipeline structure and pharma-licensing revenue approach.
- TherapeuticsMD: Women's health company focused on menopause, contraception, and prenatal vitamins with a commercial-stage franchise; comparable therapeutic focus even though TherapeuticsMD has reached commercialization.
Broad incumbents
- Organon: Large established women's health company spun out of Merck, with a broad franchise in contraception, fertility, and menopause; broader portfolio player but directly relevant comparator for any commercialized women's health asset.
- Ferring Pharmaceuticals: Global pharma with leading fertility and reproductive health franchise including Bravelle and Menopur; directly comparable end market and the type of strategic acquirer/licensee relevant to Celmatix's FSH agonist.
- Gedeon Richter: Hungarian pharma that acquired Celmatix's discovery portfolio in 2026; operates an established women's health and CNS franchise and is the most directly relevant acquirer counterparty for any future Celmatix deal.
- Astellas Pharma: Global pharma with reproductive health and women's health therapeutic franchises including fertility treatments; broad incumbent that competes in the same end markets as Celmatix's pipeline.
Emerging players
- Forendo Pharma: Clinical-stage women's health biotech focused on endometriosis and other gynecological conditions with novel non-hormonal mechanisms; directly comparable early-stage endometriosis pipeline.
- DotLab: Diagnostics company focused on endometriosis biomarkers; partial overlap given Celmatix's endometriosis drug programs and prior genomics work in the same indication.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Celmatix social profiles
Digital presenceCelmatix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Celmatix leadership team
Management profileNumber of profiles
Profiles4 records
Celmatix subsidiaries and ownership
Company hierarchySubsidiaries1 record
Celmatix funding detail
Funding detailFunding overview
Funding rounds11 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Celmatix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Celmatix
What does Celmatix do?
Celmatix is a preclinical-stage women's health biotech that discovers and develops novel therapeutics targeting ovarian biology and reproductive conditions including infertility, endometriosis, PCOS, and ovarian aging. Its core assets are drug programs — an oral FSH receptor agonist, a JNK inhibitor, AMH-targeting antibodies, and peripherally preferred melatonin receptor agonists — that are advanced through internal R&D and academic collaborations and ultimately licensed or sold to pharmaceutical partners. The company also offers a free consumer-facing fertility insights tool, MyFertility Compass.
Is Celmatix a public or private company?
Celmatix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Celmatix founded?
Celmatix was founded in 2009. It employs 101 to 250 people.
Where is Celmatix based?
Celmatix is headquartered in New York, United States, in the North America region.
How does Celmatix make money?
Two revenue lines are on record. Licensing and asset sales are the primary driver. The others are research funding and grants.
Who are Celmatix's main competitors?
Direct peers on record are ObsEva, Myovant Sciences, Dare Bioscience and TherapeuticsMD. Broad incumbents are Organon, Ferring Pharmaceuticals, Gedeon Richter and Astellas Pharma. Emerging players are Forendo Pharma and DotLab.
Does Celmatix have an API?
No public API is recorded for Celmatix.
What industry is Celmatix in?
Celmatix's product category is Women's Health Therapeutics / Reproductive Health Drug Discovery. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.